Physician profile
Katie S Murray
NPI 1235372715
$574,806.87
in general payments reported to CMS, 2019-2025
27 companies · $211K in 2025
The $211K reported for 2025 was more than what 99% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $438 · 2020: $2,718 · 2021: $81K · 2022: $28K · 2023: $127K · 2024: $124K · 2025: $211K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $281K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $68K · Travel and Lodging: $55K · Consulting Fee: $43K · Food and Beverage: $16K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $281,050.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $67,850.00 |
| Travel and Lodging | $54,818.53 |
| Consulting Fee | $43,447.50 |
| Food and Beverage | $15,568.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $467,800.12 | 2021-2025 | Jelmyto |
| Ferring Pharmaceuticals INC. | $78,083.78 | 2024-2025 | Adstiladrin |
| Janssen Scientific Affairs, LLC | $9,431.65 | 2024-2025 | Erleada, Balversa, Pipeline |
| Janssen Biotech, INC. | $5,919.03 | 2019-2025 | Erleada |
| Janssen Global Services, LLC | $3,321.14 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $2,300.00 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $2,148.00 | 2021 | |
| Boston Scientific Corporation | $1,621.60 | 2019-2025 | Lithovue |
| Immunitybio, INC. | $1,534.04 | 2025 | |
| Coloplast Corp | $626.25 | 2020-2025 | Speedicath |
| Astellas Pharma US INC | $318.99 | 2021-2022 | |
| Janssen Research & Development, LLC | $280.00 | 2022-2023 | |
| Cook Incorporated | $250.00 | 2023 | |
| Pfizer INC. | $168.13 | 2025 | |
| Kerecis Limited | $150.62 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $146.58 | 2020-2024 | |
| Procept Biorobotics Corporation | $146.20 | 2024 | Aquabeam System |
| Bayer Healthcare Pharmaceuticals INC. | $143.26 | 2025 | |
| Merck Sharp & Dohme LLC | $121.46 | 2021-2025 | |
| Ambu INC. | $55.40 | 2020 | |
| Laborie Medical Technologies Corp. | $54.76 | 2025 | Optilume Bph Drug Coated Balloon Catheter |
| Medtronic USA, INC. | $48.71 | 2019 | |
| Myovant Sciences INC. | $46.88 | 2022 | |
| Ethicon US, LLC | $38.82 | 2022 | |
| Dendreon Pharmaceuticals LLC | $27.69 | 2022 | |
| Intuitive Surgical, INC. | $23.76 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Murray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.